SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pascual-Ramos, V
Right arrow Articles by Alcocer-Varela, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pascual-Ramos, V
Right arrow Articles by Alcocer-Varela, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity

V Pascual-Ramos

B Hernández-Cruz

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México

I Villalobos

J Sifuentes-Osornio

Department of Infectious diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México

J Alcocer-Varela

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubir án, Vasco de Quiroga 15, Tlalpan, CP 14000, México DF, Méxicojalcocee{at}mailer.main.conacyt.mx

Cutaneous anergy in SLE patients results from disease activity and/or immunosuppressive treatment (IT). The aim of this study was to evaluate purified protein derivative (PPD) reaction in SLE patients. A total of 145 patients and 20 controls were studied. Five units of PPD were applied on day 0, and skin reaction was measured after 3 (PPD1) and 6 (PPD2) days. A booster was applied (day 14), and the reaction was measured after 3 (PPD3) and 6 (PPD4) days.

Non-parametricANOVA test and unpaired Student's t-test were performed. Forty patients (group I) were inactive (MexSLEDAI 3), receiving no IT (at least 3 months previous to the PPD test); 39 (group II) were inactive receiving IT; 24 (group III) were active without IT, and 42 (group IV) were active with IT. Active patients had lower PPD1 (group III, 1.4 ± 0.9; group IV, 0.6 ± 0.5) than inactive patients (group I, 8.4 ± 2.3; group II, 5.1 ± 1.9) and than controls (9.4 ± 3; P ≤ 0.001). Group IV had lower delayed response (PPD2 = 0.3 ± 0.3) than inactive groups (group I, 2.6 ± 0.9; group II, 3.1 ± 0.8) and than controls (7.9 ± 2.5; P ≤ 0.001). Group III had lower delayed reaction P ≤ 0.001).

Active SLE patients, receiving or not receiving IT, had lower skin response to PPD than inactive patients and controls.

Key Words: SLE • anergy • PPD • cellular immunity

Lupus, Vol. 11, No. 1, 25-30 (2002)
DOI: 10.1191/0961203302lu142oa
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement